Pharmacokinetic Study of Cefotaxime (CTX) in Dogs.

Synergistic effects of baicalein with cefotaxime against Klebsiella pneumoniae through inhibiting CTX-M-1 gene expression.

CTX-M-1 β-lactamase expression in Escherichia coli is dependent on cefotaxime concentration, growth phase and gene location.

An insight into the biophysical characterization of different states of cefotaxime hydrolyzing β-lactamase 15 (CTX-M-15).

Pharmacokinetic study and evaluation of the safety of taurolidine for dogs with osteosarcoma.

Antibiotic prophylaxis with cefotaxime in endoscopic extraction of upper urinary tract stones: a randomized study. The Cefotaxime Cooperative Group.

Faecal Escherichia coli isolates from healthy dogs harbour CTX-M-15 and CMY-2 β-lactamases.

Pharmacokinetics of cefotaxime.

Pharmacokinetic study of netilmicin.

Translational Inhibition of CTX-M Extended Spectrum β-Lactamase in Clinical Strains of Escherichia coli by Synthetic Antisense Oligonucleotides Partially Restores Sensitivity to Cefotaxime.

A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants.

A validated method for quantifying entecavir in biological matrices and its application in a pharmacokinetic study in rats and dogs.

Safety, tolerability and pharmacokinetic properties of the novel triazene TriN 2755 in tumour bearing dogs - a phase I study†.

Cefotaxime and nephrotoxicity.

Pharmacokinetic profiles of the analgesic flupirtine in dogs after the administration of four pharmaceutical formulations.

Pharmacokinetic Studies of Sustained-Release Depot of Dexamethasone in Beagle Dogs.

Advancing novel anesthetics: pharmacodynamic and pharmacokinetic studies of cyclopropyl-methoxycarbonyl metomidate in dogs.

Pharmacokinetic Profiles of Meloxicam and Sustained-release Buprenorphine in Prairie Dogs (Cynomys ludovicianus).

Pharmacokinetic Analysis of an Oral Multicomponent Joint Dietary Supplement (Phycox®) in Dogs.

Pharmacokinetic studies of a potent glucocorticoid (budesonide) in dogs by high-performance liquid chromatography.

Pharmacokinetic profiles of the novel COX-2 selective inhibitor cimicoxib in dogs.

pharmacodynamic integration of marbofloxacin after intravenous and intramuscular administration in beagle dogs.

Pharmacokinetic Profiles of Meloxicam and Sustained-release Buprenorphine in Prairie Dogs (Cynomys ludovicianus).

Pharmacokinetic and metabolic disposition of p-chloro-m-xylenol (PCMX) in dogs.

High prevalence of CTX-M-15 and first report of CTX-M-3, CTX-M-22, CTX-M-28 and plasmid-mediated AmpC beta-lactamase producing Enterobacteriaceae causing urinary tract infections in Bosnia and Herzegovina in hospital and community settings.

Suggest Documents

Synergistic effects of baicalein with cefotaxime against Klebsiella pneumoniae through inhibiting CTX-M-1 gene expression.

CTX-M-1 β-lactamase expression in Escherichia coli is dependent on cefotaxime concentration, growth phase and gene location.

An insight into the biophysical characterization of different states of cefotaxime hydrolyzing β-lactamase 15 (CTX-M-15).

Pharmacokinetic study and evaluation of the safety of taurolidine for dogs with osteosarcoma.

Antibiotic prophylaxis with cefotaxime in endoscopic extraction of upper urinary tract stones: a randomized study. The Cefotaxime Cooperative Group.

Faecal Escherichia coli isolates from healthy dogs harbour CTX-M-15 and CMY-2 β-lactamases.

Pharmacokinetics of cefotaxime.

Pharmacokinetic study of netilmicin.

Translational Inhibition of CTX-M Extended Spectrum β-Lactamase in Clinical Strains of Escherichia coli by Synthetic Antisense Oligonucleotides Partially Restores Sensitivity to Cefotaxime.

A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants.

A validated method for quantifying entecavir in biological matrices and its application in a pharmacokinetic study in rats and dogs.

Safety, tolerability and pharmacokinetic properties of the novel triazene TriN 2755 in tumour bearing dogs - a phase I study†.

Cefotaxime and nephrotoxicity.

Pharmacokinetic profiles of the analgesic flupirtine in dogs after the administration of four pharmaceutical formulations.

Pharmacokinetic Studies of Sustained-Release Depot of Dexamethasone in Beagle Dogs.

Advancing novel anesthetics: pharmacodynamic and pharmacokinetic studies of cyclopropyl-methoxycarbonyl metomidate in dogs.

Pharmacokinetic Profiles of Meloxicam and Sustained-release Buprenorphine in Prairie Dogs (Cynomys ludovicianus).

Pharmacokinetic Analysis of an Oral Multicomponent Joint Dietary Supplement (Phycox®) in Dogs.

Pharmacokinetic studies of a potent glucocorticoid (budesonide) in dogs by high-performance liquid chromatography.

Pharmacokinetic profiles of the novel COX-2 selective inhibitor cimicoxib in dogs.

pharmacodynamic integration of marbofloxacin after intravenous and intramuscular administration in beagle dogs.

Pharmacokinetic Profiles of Meloxicam and Sustained-release Buprenorphine in Prairie Dogs (Cynomys ludovicianus).

Pharmacokinetic and metabolic disposition of p-chloro-m-xylenol (PCMX) in dogs.

High prevalence of CTX-M-15 and first report of CTX-M-3, CTX-M-22, CTX-M-28 and plasmid-mediated AmpC beta-lactamase producing Enterobacteriaceae causing urinary tract infections in Bosnia and Herzegovina in hospital and community settings.

Pharmacokinetic Study of Cefotaxime (CTX) in Dogs.

Recommend Documents

Follow Us